(编辑：林辰)关键字： 医药 下半年，公司管理层将进一步聚焦现有业务板块发展，加大市场拓展力度，盘活资产，提升经营业绩水 平，为股东创造更大价值。 （上证路演） 9月25日，济民健康举办2025年半年度业绩说明会。会上管理层回应，截至目前，公安机关已初步查明 "何清红等人伪造公司印章"案的基本事实，何清红已由黄岩区检察院批准逮捕，相关案件仍在进一步侦 查中。目前，公司的新药研发项目均按计划稳步推进中，如果新的进展，公司将依照规则进行披露。目 前公司经营正常，各板块稳健发展，公司管理层将努力提升经营管理水平。 此外，管理层还提到，公司将充分利用海南博鳌乐城先行区的创新政策，进一步加强对外合作，加大对 创新药的研发投入，将博鳌国际医院打造成为高水平的临床研究中心和转化医学平台。 公司目前持有博鳌国际医院51%的股权。其他49%的股份包括公司控股股东双鸽集团及其他自然人，涉 及多方利益。公司后续如有相关安排或进展，公司将及时披露相关信息。 ...

Group 1 - The company hosted an investor relations event on September 25, 2025, attracting participation from 10 institutions, including Shenzhen Beidouxing Space Investment Company [1] - The event included discussions on the company's operating performance, product layout, market development, and production management, aligning with the company's announcements [1] - Key personnel from the company included the Deputy General Manager and Board Secretary, Financial Director, and Securities Affairs Specialists [1] Group 2 - The company's subsidiary, Huason Yingnuo, is responsible for innovative drug development and has transitioned to a clinical-stage biotechnology company [2] - As of 2025, the company has 7 self-initiated innovative drug projects in development, targeting oncology and autoimmune diseases, with one drug currently in clinical trials [2] - In the first half of 2025, the company achieved revenue of 442 million yuan, a year-on-year increase of 5.76%, driven by the approval and successful bidding of chemical generic drugs [2] Group 3 - The company’s five key traditional Chinese medicine products are focused on common and chronic diseases, with 29 authoritative recommendations received [3] - The sales strategy primarily targets public hospitals, with a significant portion of sales occurring in the hospital market, while also expanding into retail pharmacies and e-commerce [3] - The company has four self-developed special medical food projects, with one project already certified and in the market introduction phase [3] Group 4 - The weight loss drug, Quchang Orlistat capsules, is currently in the market introduction phase as part of the company's health product portfolio [4]

Core Viewpoint - The announcement indicates that the company's subsidiary, Bochuangyuan, has received approval from the National Medical Products Administration for a clinical trial of CKBA cream for the treatment of rosacea, marking a significant step in the development of innovative drugs in the industry [1] Company Summary - The approved clinical trial is for a seamless Phase II/III study of CKBA cream, which is an innovative Class 1 chemical drug developed by Bochuangyuan [1] - The approval is not expected to have a significant short-term impact on the company's financial status or operating performance [1] - The development of innovative drugs is characterized by long cycles and high investment, with potential risks related to industry policies and uncertain outcomes [1] Industry Summary - Currently, there are no approved Class 1 innovative drugs for the treatment of rosacea in the domestic market, highlighting a pressing need for safe, effective, and low-side-effect innovative medications to meet clinical demands [1]

Group 1: Company Overview and Performance - The company achieved a revenue of 442 million CNY in the first half of 2025, an increase of 5.76% compared to the same period last year [4] - The net profit attributable to shareholders reached 53.95 million CNY, up 14.27% year-on-year [4] - The growth in revenue was driven by a 29.45% increase in revenue from chemical generic drugs and a 3.52% increase in key traditional Chinese medicine (TCM) products [4] Group 2: Research and Development - The company’s subsidiary, Huason Yingnuo, has seven innovative drug projects in clinical stages, covering various cancers and autoimmune diseases [3] - The innovative drug ORIC-1940 is currently undergoing Phase Ia/Ib clinical trials [3] - The company has successfully integrated with Chengdu Aorui Pharmaceutical, enhancing its R&D capabilities [3] Group 3: Product Development and Market Strategy - The company has five key TCM products that are essential for common and chronic diseases, with sales growth of 3.52% in the first half of 2025 [6][7] - The TCM product Pain Relief Granules saw sales increase by over 30% [7] - The company is focusing on building an academic system for key products and promoting them in clinical guidelines [7] Group 4: Sales Channels and Market Expansion - Approximately 70% of sales are generated from public hospitals, with efforts to expand into retail pharmacies and e-commerce platforms [8] - The company is actively working to increase its market share in outpatient clinics and other healthcare settings [8] Group 5: Special Medical Foods - The global market for special medical foods is approximately 3 billion USD, with China's market at around 7 billion CNY [9] - The company has four self-developed projects in this category and has received regulatory approval for its first special medical food product [11] - The production line for special medical foods is expected to gradually release capacity as new products are launched [11]

Core Viewpoint - The collaboration between Xiao Fang Pharmaceutical and Boji Pharmaceutical marks a significant step in the development of innovative drugs, particularly in the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - Xiao Fang Pharmaceutical has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical to assist in the clinical research and registration of a Class 1 traditional Chinese medicine compound [1] - This partnership is based on a shared strategic development vision, indicating a strong alliance between the two companies [1] Group 2: Strategic Implications - The collaboration is expected to leverage Boji Pharmaceutical's strengths in research and development, technical expertise, and clinical resources, enhancing the efficiency and success rate of the product's development [1] - The partnership aims to establish a solid foundation for the subsequent application and market launch of the product [1]

Core Viewpoint - The collaboration between the company and Boji Pharmaceutical Technology Co., Ltd. marks a significant step in the company's strategic development in the innovative drug sector, focusing on the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - The company has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical, which will assist in completing the clinical research and registration of a Class 1 compound medicine [1] - This partnership is described as a strong alliance based on a shared development strategy, leveraging the strengths of both parties [1] Group 2: Advantages of Collaboration - Boji Pharmaceutical is recognized as an industry leader with significant advantages in research and development capabilities, technical accumulation, and clinical resources [1] - The collaboration is expected to create a synergistic effect, enhancing the research and development efficiency and success rate of the contracted product [1] - This partnership aims to lay a solid foundation for the subsequent application and market launch of the product [1]

Group 1 - The core viewpoint of the article highlights that Wanbangde's self-developed innovative small molecule cyclic peptide drug (MCR cyclic peptide) shows superior weight loss effects compared to the existing star drug GLP-1 peptide in preclinical studies on DB/DB obese mouse models [1] - The drug also demonstrates muscle preservation and comprehensive regulation of metabolic indicators such as blood sugar and blood lipids, indicating potential for differentiated clinical options [1] - Wanbangde has established a comprehensive R&D system and a highly skilled team, transitioning from generic drugs to innovative drugs, focusing on the development of traditional Chinese medicine, chemical drugs, and raw materials [1] Group 2 - As of the first half of this year, Wanbangde holds 67 patents in the pharmaceutical manufacturing sector, including 50 invention patents, 14 utility model patents, and 3 design patents [1] - The company’s key product, Huperzine A, has obtained patents in the United States, Europe, and Japan, with an additional 7 patents expected to be added by the first half of 2025 [1] - The company plans to continue advancing the preclinical pharmacology and toxicology studies of its peptide new drugs, aiming to bring differentiated medications to patients with relevant treatment needs [2]

Group 1 - The core point of the article is the recent business change of Shanghai Minwei Biotechnology Co., Ltd., which has added Guangxi Tencent Venture Capital Co., Ltd. as a shareholder and increased its registered capital to approximately 16.16 million yuan [1] - Shanghai Minwei Biotechnology Co., Ltd. was established in 2021 and is focused on the development of innovative "multi-core macromolecular biopharmaceuticals" and platform development [1] - The major shareholder of Shanghai Minwei Biotechnology is Lepu Medical (300003), indicating a strategic partnership in the biopharmaceutical sector [1]

Group 1 - The company held its fifth board meeting on September 24, 2025, where all eight directors attended and approved the extension of the commitment period for a supplementary agreement related to the A-round capital increase of its subsidiary [2][3][24] - The board approved the proposal for the transfer of equity and capital increase of its subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., allowing the introduction of important investors while waiving the company's preemptive rights [6][7][20] - The total pre-investment valuation of Guangsheng Zhonglin was confirmed at RMB 250 million, with the overall valuation post-transaction reaching RMB 269.135 million [10][20] Group 2 - The company and Guangsheng Zhonglin have signed relevant agreements with other parties involved in the transaction, completing their internal decision-making processes [8][20] - The investment agreement includes specific conditions for the payment of investment funds, which must be fulfilled within a set timeframe [12][13][20] - The supplementary agreement extends the commitment period and adjusts the equity repurchase terms, facilitating a focus on the core business of innovative drug development [25][26]

（来源：研报虎） 2025年上半年业绩逐步企稳，盈利能力持续提升。2025年上半年公司实现营收62.72亿元(-0.2%)，归母 净利润12.81亿元(+9.4%)，扣非归母净利润12.58亿元(+8.9%)。2025年二季度营收30.91亿元(+1.7%)，归 母净利润6.44亿元(+14.4%)，扣非归母净利润6.40(+13.2%)。 分板块看，2025年上半年化学制剂板块销售收入32.70亿元(+1.4%)，其中消化道药品销售额为13.51亿元 (+3.9%)，促性激素药品销售额为15.30亿元(-1.2%)，精神类药品销售额为3.17亿元(+6.9%)，抗感染及其 他产品销售额为0.72亿元(-7.4%)，板块整体的毛利率为81.17%(+0.02pp)；中药制剂2025年上半年销售收 入7.99亿元(+7.3%)，毛利率为74.0%(-1.57pp)；原料药及中间体2025年上半年销售收入16.62亿元 (-5.7%)，毛利率为36.37%(-0.76pp)；诊断试剂及设备产品2025年上半年销售收入3.74亿元(-5.1%)，生物 制品板块2025年上半年销售收入0.95亿元(+8.3%)。 I ...